American Capital Ventures, Inc. ("ACV") is a company comprised of
industry professionals with over 45 years of collective experience
in the brokerage and investor relations industries. ACV President
Howard Gostfrand stated, "We are pleased to be able to spearhead
Pluristem's efforts to bring their financial story to the investment
community. Their potential market is enormous and we are highly
confident in management's ability to be a leader in their space."
"At this stage in Pluristem's growth we are excited to be able to
cede the responsibilities of investor relations to such a
professional group. Hiring ACV will give us the chance to truly
focus on our business. Pluristem is making great progress and we are
thrilled to be able to have our story presented to a wider
audience," said Zami Aberman, Chairman and CEO of Pruristem.
About Pluristem Life Systems, Inc.
Pluristem Life Systems, Inc. is a Company dedicated to the
commercialization of non-personalized (allogeneic) stem cell therapy
products for the treatment of numerous severe degenerative,
malignant and autoimmune disorders. The Company's first planned
product, PLX-BMT, targets a $2 billion market and is intended to
resolve the global shortfall of matched tissue for bone marrow
transplantation (BMT) by improving the engraftment of hematopoietic
stem cells (HSCs) contained in umbilical cord blood (CB).
Pluristem's products are derived from mesenchymal stem cells
(MSCs) obtained from the placenta and expanded in the Company's
proprietary PluriX(TM) 3D bioreactor that imitates the natural
microstructure of bone marrow and does not require supplemental
growth factors, cytokines or other exogenous materials. Pluristem
believes the resultant expanded cells, termed PLX cells, are
multipotent and able to differentiate into a variety of cell types
as well as being immune-privileged to protect the recipient from
immunological reactions that often accompanies transplantation.
Pluristem believes their future products will participate in the
approximate $30 billion therapeutic and regenerative cellular
market.
Pluristem has offices and is incorporated in the USA with
research and manufacturing facilities in Israel.
www.pluristem.com
Safe Harbor Statement
This press release contains statements, which may constitute
"forward-looking statements" regarding our intent, belief or current
expectations. Forward-looking statements in this release include
factors that could prevent our forward looking statements from being
achieved include that we may be unable to get regulatory approval
for our products; we may be unsuccessful in developing any products;
our technology may not be validated as we progress further and our
methods may not be accepted by the scientific community; we may be
unable to retain or attract key employees whose knowledge is
essential to the development of our products; unforeseen scientific
difficulties may develop with our process; results in the laboratory
may not translate to equally good results in real surgical settings;
our patents may not be sufficient to protect essential aspects of
our technology; competitors may invent better technology; our
products may not work as well as hoped or worse, our products may
harm recipients; and we may not be able to raise funds for
development or working capital when we require it. As well, our
products may never develop into useful products and even if they do,
they may not be approved for sale to the public. For further risk
factors see the Company's latest 10-KSB filed with the SEC.
For more information visit our website at
www.pluristem.com
